THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development ...

Lexicon Pharmaceuticals shares jumped nearly 75 ... agreement potentially worth $1 billion with Danish drug maker Novo Nordisk. Shares of Lexicon, based in The Woodlands, Texas, were recently ...

Novo Nordisk is expanding its obesity drug pipeline through a major licensing agreement with Lexicon Pharmaceuticals, acquiring the global rights to LX9851, a first-in-class oral therapy targeting ...

Lexicon Pharmaceuticals secured a licensing deal with Novo Nordisk for LX9851, with potential payments totaling $1 billion-plus royalties. Preclinical data show that LX9851 enhances weight loss ...

March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...